Use of fulvestrant for the therapeutic care of central core disease
AssigneesUniversite Grenoble Alpes, Institut National de la Sante et de la Recherche Medicale, Centre Hospitalier Universitaire Grenoble Alpes, Association Francaise Contre Les Myopathies
InventorsIsabelle MARTY, Laurent PELLETIER, Lauriane TRAVARD
Life of this patent
Estimating the term…
Abstract
Disclosed is an estrogen receptor antagonist of formula: for use in the treatment of a disease or disorder related to a decrease in calcium release between the sarcoplasmic reticulum and the cytosol, in particular the disease or disorder is a myopathy related to one or more mutations of the RyR1 gene or a myopathy linked to a decrease in calcium release, and more particularly central core disease. Also disclosed is a pharmaceutical composition including at least the oestrogen receptor antagonist of and at least one pharmaceutically acceptable excipient.
Claims9
A method of treatment of a disease or disorder related to a decrease in calcium release between the sarcoplasmic reticulum and the cytosol, comprising administering a therapeutically effective dose of estrogen receptor antagonist of formula:
- to a patient in need thereof.
4-5. (canceled)
A pharmaceutical composition comprising:
- an estrogen receptor antagonist of formula:
- at least one pharmaceutically acceptable excipient.
Dependencies are inferred from the claim text.